{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:19:37Z","timestamp":1784920777382,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF W1241"],"award-info":[{"award-number":["FWF W1241"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.bbalip.2021.158943","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T20:09:19Z","timestamp":1618344559000},"page":"158943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function"],"prefix":"10.1016","volume":"1866","author":[{"given":"Athina","family":"Trakaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Weger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas O.","family":"Eichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Scharnagl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia T.","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Salmhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Knuplez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunther","family":"Marsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbalip.2021.158943_bb0005","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet."},{"key":"10.1016\/j.bbalip.2021.158943_bb0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0015","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bbalip.2021.158943_bb0020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0030","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0045","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet."},{"key":"10.1016\/j.bbalip.2021.158943_bb0050","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s13671-018-0210-4","article-title":"Effects of biologic therapy on cardiovascular disease in psoriasis","volume":"7","author":"Henning","year":"2018","journal-title":"Curr. Dermatol. Rep."},{"key":"10.1016\/j.bbalip.2021.158943_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/CIRCIMAGING.112.975730","article-title":"Effects of the tumor necrosis factor-\u03b1 antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial","volume":"6","author":"Bissonnette","year":"2013","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"10.1016\/j.bbalip.2021.158943_bb0060","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-\u03b1 antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study","volume":"137","author":"Bissonnette","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0065","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1001\/jamadermatol.2016.1984","article-title":"Association between changes in coronary artery disease progression and treatment with biologic agents for severe psoriasis","volume":"152","author":"Hjuler","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2020.2977","article-title":"Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody Ustekinumab","author":"Poizeau","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0075","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S2213-8587(15)00126-6","article-title":"Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study","volume":"3","author":"Saleheen","year":"2015","journal-title":"Lancet Diab. Endocrinol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0085","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0090","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1093\/eurheartj\/ehv339","article-title":"Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis","volume":"36","author":"Salahuddin","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbalip.2021.158943_bb0095","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1194\/jlr.M027367","article-title":"Psoriasis alters HDL composition and cholesterol efflux capacity","volume":"53","author":"Holzer","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0100","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2012.06.068","article-title":"Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis","volume":"224","author":"Mehta","year":"2012","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.bbalip.2021.158943_bb0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/biomedicines8120558","article-title":"High-density lipoprotein (HDL) in allergy and skin diseases: focus on immunomodulating functions","volume":"8","author":"Trakaki","year":"2020","journal-title":"Biomedicines."},{"key":"10.1016\/j.bbalip.2021.158943_bb0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/jid.2013.359","article-title":"Anti-psoriatic therapy recovers high-density lipoprotein composition and function","volume":"134","author":"Holzer","year":"2014","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0115","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1161\/CIRCRESAHA.118.313608","article-title":"Association between oxidation-modified lipoproteins and coronary plaque in psoriasis an observational cohort study","volume":"123","author":"Sorokin","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0120","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1016\/j.bbalip.2019.06.007","article-title":"Allergic rhinitis is associated with complex alterations in high-density lipoprotein composition and function","volume":"1864","author":"Trakaki","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids."},{"key":"10.1016\/j.bbalip.2021.158943_bb0125","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1194\/jlr.D075366","article-title":"HDL structure and function is profoundly affected when stored frozen in the absence of cryoprotectants","volume":"58","author":"Holzer","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2006-05-022954","article-title":"Human Langerhans-cell activation triggered in vitro by conditionally expressed MKK6 is counterregulated by the downstream effector RelB","volume":"109","author":"J\u00f6rgl","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.bbalip.2021.158943_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-08136-1","article-title":"Secretory phospholipase A2modified HDL rapidly and potently suppresses platelet activation","volume":"7","author":"Curcic","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2021.158943_bb0140","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1161\/ATVBAHA.117.309201","article-title":"Large-scale analysis of determinants, stability, and heritability of high-density lipoprotein cholesterol efflux capacity","volume":"37","author":"Koekemoer","year":"2017","journal-title":"Arterioschler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0145","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1210\/jc.2017-00933","article-title":"Adiponectin predicts high-density lipoprotein cholesterol efflux capacity in adults irrespective of body mass index and fat distribution","volume":"102","author":"Marsche","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bbalip.2021.158943_bb0150","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1194\/jlr.M500187-JLR200","article-title":"Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux","volume":"46","author":"Asztalos","year":"2005","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0155","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/ATVBAHA.109.199158","article-title":"The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages","volume":"30","author":"Llera-Moya","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep38533","article-title":"Refined purification strategy for reliable proteomic profiling of HDL 2\/3: impact on proteomic complexity","volume":"6","author":"Holzer","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbalip.2021.158943_bb0165","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":"Antiinflammatory properties of HDL","volume":"95","author":"Barter","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0170","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jacl.2018.08.007","article-title":"Feasibility of a plasma bioassay to assess oxidative protection of low-density lipoproteins by high-density lipoproteins","volume":"12","author":"Swertfeger","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0175","series-title":"High Density Lipoproteins","first-page":"3","article-title":"Structure of HDL: particle subclasses and molecular components","author":"Kontush","year":"2015"},{"key":"10.1016\/j.bbalip.2021.158943_bb0180","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.molmed.2011.05.013","article-title":"Biological activities of HDL subpopulations and their relevance to cardiovascular disease","volume":"17","author":"Camont","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2310\/7750.2013.13125","article-title":"Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab","volume":"18","author":"Tausend","year":"2014","journal-title":"J. Cutan. Med. Surg."},{"key":"10.1016\/j.bbalip.2021.158943_bb0190","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbalip.2021.158943_bb0200","unstructured":"L. Fala, Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am. Heal. Drug Benefits. 9 (2016) 60\u20133."},{"key":"10.1016\/j.bbalip.2021.158943_bb0205","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.4049\/jimmunol.175.4.2721","article-title":"TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques","volume":"175","author":"Gottlieb","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11926-004-0041-0","article-title":"Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective","volume":"6","author":"Kane","year":"2004","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bbalip.2021.158943_bb0215","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0220","doi-asserted-by":"crossref","unstructured":"T. Tzellos, A. Kyrgidis, A. Trigoni, C.C. Zouboulis, Association of ustekinumab and briakinumab with major adverse cardiovascular events: an appraisal of meta-analyses and industry sponsored pooled analyses to date, Dermatoendocrinol. 4 (2012) 320\u20133. doi:https:\/\/doi.org\/10.4161\/derm.23100.","DOI":"10.4161\/derm.23100"},{"key":"10.1016\/j.bbalip.2021.158943_bb0225","first-page":"864","article-title":"Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials","volume":"306","author":"Ryan","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.bbalip.2021.158943_bb0230","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: results from the German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0235","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5\u00a0years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0240","first-page":"1002","article-title":"Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis","volume":"16","author":"Bissonnette","year":"2017","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0245","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0250","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Kerkhof","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0255","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12675","article-title":"Secukinumab reduces plasma oxidative stress in psoriasis: a case-based experience","volume":"31","author":"Becatti","year":"2018","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.bbalip.2021.158943_bb0260","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1111\/1346-8138.14545","article-title":"Improvement in abnormal coronary arteries estimated by coronary computed tomography angiography after secukinumab treatment in a Japanese psoriatic patient","volume":"46","author":"Yamazaki","year":"2019","journal-title":"J. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0265","first-page":"100","article-title":"Effects of interleukin 17A inhibition on myocardial deformation and vascular function in psoriasis, can","volume":"36","author":"Makavos","year":"2020","journal-title":"J. Cardiol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S)","author":"Gelfand","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0275","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jid.2018.10.042","article-title":"Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52\u00a0weeks","volume":"139","author":"Stebut","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0280","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1016\/j.jacc.2018.09.080","article-title":"Association of serum cholesterol efflux capacity with mortality in patients with ST-segment elevation myocardial infarction","volume":"72","author":"Guerin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0285","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pharmthera.2012.12.001","article-title":"Inflammation alters HDL composition and function: implications for HDL-raising therapies","volume":"137","author":"Marsche","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbalip.2021.158943_bb0290","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1161\/CIRCRESAHA.116.305485","article-title":"HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export","volume":"116","author":"Du","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0295","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/MOL.0b013e328338472d","article-title":"High-density lipoprotein heterogeneity and function in reverse cholesterol transport","volume":"21","author":"Rothblat","year":"2010","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051149","article-title":"An updated review of lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbalip.2021.158943_bb0305","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1194\/jlr.RA119000258","article-title":"Composition-function analysis of HDL subpopulations: influence of lipid composition on particle functionality","volume":"61","author":"Niisuke","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0310","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1172\/JCI119554","article-title":"Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles","volume":"100","author":"Castellani","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbalip.2021.158943_bb0315","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0022-2275(20)31165-2","article-title":"In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions","volume":"42","author":"Hedrick","year":"2001","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.bbalip.2021.158943_bb0320","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1161\/01.ATV.15.9.1412","article-title":"Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I\/A-II in native plasma","volume":"15","author":"Huang","year":"1995","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0325","doi-asserted-by":"crossref","first-page":"23098","DOI":"10.1016\/S0021-9258(19)49431-3","article-title":"High density lipoprotein conversion mediated by human plasma phospholipid transfer protein","volume":"268","author":"Tu","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2021.158943_bb0330","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/S0021-9258(18)53575-4","article-title":"Human plasma phospholipid transfer protein causes high density lipoprotein conversion","volume":"268","author":"Jauhiainen","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbalip.2021.158943_bb0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ. Cardiovasc. Imaging."},{"key":"10.1016\/j.bbalip.2021.158943_bb0340","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/art.39039","article-title":"Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism","volume":"67","author":"Ronda","year":"2015","journal-title":"Arthr. Rheumatol."},{"key":"10.1016\/j.bbalip.2021.158943_bb0345","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/art.39675","article-title":"Effect of drug therapy on net cholesterol efflux capacity of high-density lipoprotein\u2013enriched serum in rheumatoid arthritis","volume":"68","author":"Ormseth","year":"2016","journal-title":"Arthr. Rheumatol."},{"issue":"4","key":"10.1016\/j.bbalip.2021.158943_bb0350","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0014-5793(91)80962-3","article-title":"Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein","volume":"286","author":"Mackness","year":"1991","journal-title":"Fed. Eur. Biochem. Soc."},{"key":"10.1016\/j.bbalip.2021.158943_bb0355","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/iub.588","article-title":"Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation","volume":"64","author":"Hine","year":"2012","journal-title":"IUBMB Life"},{"key":"10.1016\/j.bbalip.2021.158943_bb0360","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/0304-4165(87)90155-3","article-title":"The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma","volume":"924","author":"Wayner","year":"1987","journal-title":"BBA - Gen. Subj."},{"key":"10.1016\/j.bbalip.2021.158943_bb0365","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.febslet.2008.04.057","article-title":"The antioxidant properties of serum albumin","volume":"582","author":"Roche","year":"2008","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbalip.2021.158943_bb0370","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/BF02522884","article-title":"The chemistry and antioxidant properties of tocopherols and tocotrienols","volume":"31","author":"Kamal-Eldin","year":"1996","journal-title":"Lipids."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138819812100069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S138819812100069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:46:01Z","timestamp":1778521561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S138819812100069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S138819812100069X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbalip.2021.158943","relation":{},"ISSN":["1388-1981"],"issn-type":[{"value":"1388-1981","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbalip.2021.158943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"158943"}}